Compare FIEE & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIEE | ALLR |
|---|---|---|
| Founded | 1977 | 2004 |
| Country | Hong Kong | United States |
| Employees | 30 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 19.3M |
| IPO Year | 2010 | 2021 |
| Metric | FIEE | ALLR |
|---|---|---|
| Price | $3.02 | $0.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.3K | ★ 124.2K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.46 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $47,988,549.00 | $320,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.47 | ★ N/A |
| Revenue Growth | ★ 27.58 | N/A |
| 52 Week Low | $1.50 | $0.77 |
| 52 Week High | $10.59 | $1.84 |
| Indicator | FIEE | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 40.80 | 45.77 |
| Support Level | $2.70 | $0.90 |
| Resistance Level | $3.32 | $1.00 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 43.55 | 21.27 |
FiEE Inc is a digital service provider focused on integrating artificial intelligence (AI) and data analytics into content creation, digital authentication, and brand management. Its business model leverages a cloud-based SaaS platform designed to support clients in developing, managing, and optimizing their digital presence across platforms, including customized graphics and posts, short videos, and editorial calendars aligned with brand goals. Additionally, it offers comprehensive software development and maintenance services, delivering custom software solutions from system design and development to deployment and post-launch maintenance. It services consist of three core areas: digital content and MCN services, software development services, and digital authentication services.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.